Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Solid Tumor 1Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 27Gemcitabine 22toripalimab 19Radiotherapy, Intensity-Modulated 18Capecitabine 10Radiotherapy 8Magnetic Resonance Spectroscopy 8nimotuzumab 7camrelizumab 7Specimen Handling 7Immune Checkpoint Inhibitors 7spartalizumab 5Drug Therapy 5Docetaxel 5Nivolumab 4Biopsy 4sintilimab 3Surgical Procedures, Operative 3Radiosurgery 3Platinum 3Fluorouracil 3Endoscopy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tislelizumab 2pembrolizumab 2irinotecan sucrosofate 2envafolimab 2apatinib 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Carcinoma × Off-Label Use × Clear all
NCT04813705 2023-02-21

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Taizhou Hospital

Phase 2 Recruiting
93 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡